The Future of Cardiovascular Biologics: Projected Growth to USD 4.23 Billion by 2033

The Cardiovascular Biologics Market Overview

Recent insights reveal that the cardiovascular biologics market, currently valued at approximately USD 2.20 billion in 2024, is on track for significant expansion, with projections estimating growth to USD 4.23 billion by 2033. This represents a compound annual growth rate (CAGR) of 7.5% over the anticipated period from 2025 to 2033.

Drivers of Growth

The anticipated growth of this market is substantially attributed to the rising development of biologic therapies and gene-based treatments designed for cardiovascular disease pathways. Innovations such as monoclonal antibodies (mAbs), small interfering RNA (siRNA) therapeutics, and recombinant proteins are leading the charge. For context, cardiovascular diseases (CVDs) are responsible for approximately 18 million fatalities annually, which equals nearly 32% of all global deaths according to the World Health Organization.
The rate of therapy adoption is surging; the penetration of biologics in cardiovascular therapeutics has escalated from 3% in 2019 to a notable 9% in 2024, and forecasts suggest it could exceed 20% by 2030. As of 2024, research and development (R&D) expenditure on cardiovascular biologics has surpassed USD 2.5 billion, marking a 40% increase since 2020, primarily facilitated by advancements in mRNA and siRNA technologies. Additionally, ongoing regulatory momentum is evident, with over 45 late-stage cardiovascular biologics currently undergoing clinical trials globally, encompassing monoclonal antibodies aimed at various biological targets like PCSK9, ANGPTL3, and IL-6 pathways.

Cost-effectiveness further bolsters the appeal of biologics, with data indicating that these therapies can lower low-density lipoprotein cholesterol (LDL-C) levels by up to 60%, leading to a 27% reduction in cardiac event occurrences in high-risk populations.

Market Segmentation

The cardiovascular biologics market can be segmented across several dimensions:

By Biologic Type

- Monoclonal Antibodies (mAbs): Commanding a dominant market share of 52% (approximately USD 1.14 billion in 2024), with highly successful products like Repatha from Amgen and Praluent from Regeneron/Sanofi fueling growth. This segment is predicted to reach USD 2.2 billion by 2033, expanding at a CAGR of 7.7%.
- siRNA-Based Therapeutics: Comprising about 25% of market share (USD 550 million). This is the fastest-growing category, bolstered by clinical successes like Alnylam Pharmaceuticals’ inclisiran, which offers sustained LDL-C reduction for up to six months.
- Recombinant Proteins: Holding a 15% share, they play a role in conditions such as ischemic heart disease and heart failure.
- Others: Including gene therapies and peptide biologics, accounting for 8% of the market share, with promising potential post-2030.

By Indication

- Coronary Artery Disease (CAD): The most prevalent indication, capturing 38% of the market (USD 836 million in 2024), with predicted growth driven by the rise of PCSK9 inhibitors alongside siRNA lipid therapies.
- Heart Failure (HF): Accounts for 25%, aided by biologics targeting myocardial regeneration processes.
- Arrhythmias and Valvular Heart Diseases: Together they contribute 20% of the market, with innovative biologics enhancing both structural and electrical cardiac function.
- Hypertension: Represents a 10% share, influenced particularly by siRNA approaches addressing angiotensinogen.
- Other Conditions: Such as pulmonary hypertension and vascular inflammation, contribute to an additional 7%.

By Distribution Channel

- Hospital Pharmacies: Predominantly control 60% of the market, necessitated by specialist prescriptions and in-patient administered biologics.
- Retail Pharmacies: Comprising a 40% share, projected to exceed USD 1.7 billion by 2033, facilitated by increased patient access to self-administered biologic therapies.

Regional Insights

In the United States, the cardiovascular biologics market held a substantial 45% of the global share (valued at USD 990 million in 2024) and is expected to expand to USD 1.95 billion by 2033, registering a CAGR of 7.8%. The FDA-approved biologics such as Leqvio and Repatha play significant roles in lipid-lowering therapy, with Medicare recently including siRNA drugs for reimbursement. Notably, federal R&D grants for biologic drug development have exceeded USD 1.1 billion, underscoring the commitment to RNA-based innovation.
In Japan, the market reached USD 210 million in 2024 and is anticipated to double by 2033, fueled by the growing elderly population and recent approval of siRNA-based cardiovascular drugs.

Competitive Landscape

Competitors within this segment include industry giants such as Regeneron Pharmaceuticals, Amgen, Novartis Pharmaceuticals, and Alnylam Pharmaceuticals, all striving to innovate and capture market share. Recent developments reveal active research across various segments, indicating that investing in next-generation biologic platforms can yield substantial growth opportunities.

Conclusion

As the cardiovascular biologics market approaches a significant evolution, the insights gathered indicate a sustained growth trajectory driven by biological innovations. The transition from USD 2.20 billion in 2024 to USD 4.23 billion by 2033 marks this segment as a dynamic landscape rich with potential. Companies focusing on revolutionary biologic strategies and expanding treatment indications beyond conventional limits are poised for success.